SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
SBIR TOPIC 255, PHASE II: SYNTHETIC VACCINES AGAINST PROSTATE CANCER
SBIR 主题 255，第二阶段：针对前列腺癌的合成疫苗
批准号：
8351886
负责人：
PETER PUSHKO
金额：
$148.31万
依托单位：
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
项目状态：
已结题
起止时间：
2011-09-29 至 2013-09-28
关键词：
Animal ModelAntibody FormationAntigensBiological AssayCD8B1 geneCancer ControlChemistryCollaborationsContractsDataDendritic CellsDevelopmentDoseEngineeringEvaluationGenesGoalsHumanImmunotherapyMalignant neoplasm of prostateMarylandMethodsMusPhasePreparationProceduresProcessProductionProstate Cancer VaccineProstate-Specific AntigenPublic HealthQuality ControlRegimenResearchRouteSafetySerumSmall Business Innovation Research GrantStructure of base of prostateSynthetic VaccinesT-LymphocyteTransgenic MiceUnited States Food and Drug AdministrationUniversitiesVaccinatedVaccinationVaccine AntigenVaccine ProductionVaccinesVariantVirus-like particleassay developmentcancer immunotherapydesignexpression vectorfollow-upimmunogenicityimprovedin vivomeetingsnovelnovel therapeuticsnovel vaccinesprotective effectprotective efficacyresearch studyscale uptherapeutic vaccinetumorvaccine candidatevaccine efficacyvector
中文摘要
翻译
该二期SBIR合同用于先进的疫苗效力研究，其中涉及接种PSA+转基因小鼠的TRAMP肿瘤攻击。为提高免疫原性而设计的PSA变体将使用新型载体VLP（vVLP_vaccine platform）在PSA+小鼠中递送和表达。后者代表非复制型病毒样颗粒，其被配置为包裹表达载体以用于体内递送和表达工程化PSA基因。
英文摘要
This Phase II, SBIR contract is for the advanced vaccine efficacy studies, which involve TRAMP tumor challenge of vaccinated PSA+ transgenic mice. Engineered for increased immunogenicity PSA variants will be delivered and expressed in PSA+ mice using novel ¿vector VLP¿ (vVLP_ vaccine platform. The latter represent non-replicating virus-like particles configured to encapsidate expression vector for in vivo delivery and expression of engineered PSA genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
